Trade Ironwood Pharmaceuticals Inc - IRWD CFD

Ironwood Company profile

About Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company that is focused on the development and commercialization of GI products in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC). It operates in the human therapeutics business segment. Its product candidate LINZESS (linaclotide) is available to adult men and women suffering from IBS-C or CIC in the United States, and Mexico and to adult men and women suffering from IBS-C. Its linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries. The Company’s products pipeline includes IW-3300, which is a GC-C agonist, for the potential treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis, and CNP-104 is a tolerizing immune modifying nanoparticle.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Ironwood Pharmaceuticals, Inc. revenues increased 6% to $413.8M. Net income increased from $106.2M to $528.4M. Revenues reflect Collaborative arrangements revenue increase of 8% to $412.8M. Net income benefited from Selling, general and administrative decrease of 19% to $93.8M (expense), Research and development decrease of 21% to $65.6M (expense).

Equity composition

Common Stock Class B, $0.001 Par, 3/11, 100M auth., 50,825,074 issd. Common Stock Class A, $0.001 Par, 500M auth., 48,612,174 issd. Insider hold 0.09%.